Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Gives Stock $17.75 Price Valuation, Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals is developing a THC analog that offers the benefits of THC without its negative side effects. Zacks Small-Cap Research has given MIRA a price valuation of $17.75.
October 21, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zacks Small-Cap Research has valued MIRA Pharmaceuticals at $17.75, highlighting its development of a THC analog with benefits but without side effects.
The positive price valuation from Zacks Small-Cap Research is likely to boost investor confidence in MIRA Pharmaceuticals. The development of a THC analog that retains benefits while eliminating side effects is a significant product innovation, potentially increasing the company's market appeal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100